Pharmacy Groups: CMS Guidance Sets Up Oral Antivirals for Failure, Limiting Patients' Access to COVID-19 Treatments

Published: November 30, 2021
ASHP Press Release

A group of six pharmacy organizations today criticized the decision of the U.S. Centers for Medicare & Medicaid Services (CMS) to only “encourage” but not require payment to pharmacists for testing, patient assessment, ordering/prescribing and dispensing for oral COVID-19 antiviral drugs, potentially limiting the ability of Medicare patients to access these lifesaving medications– particularly those in rural and underserved communities.

The issue is extremely time sensitive, because a committee of the Food and Drug Administration is meeting today to determine whether to issue an Emergency Use Authorization for molnupiravir, an oral antiviral medication developed by Merck.

The group stated, “After more than a year of continuously expanding the ability of patients to access COVID-19 tests, immunizations, and therapeutics from pharmacists and other pharmacy personnel, the failure of CMS to require pharmacists to be compensated for testing, patient assessment, and ordering/prescribing, in addition to dispensing oral antivirals makes little sense and sets up the distribution program for failure. 

“CMS needs to clearly delineate a payment pathway necessary to allow pharmacists’ patients to access these lifesaving medications. With 90 percent of Americans live within five miles of a pharmacy, making them the most viable access point for patients to receive these medications. In addition, the neighborhood pharmacy in rural and underserved communities may be the only health care provider for miles.

“The federal government has made it clear we need all-hands-on-deck to defeat COVID-19 and advance health equity by authorizing pharmacists and other pharmacy personnel to order and administer oral antivirals. Without hesitation, throughout the pandemic, our nation’s frontline pharmacists have stepped up to meet the public health needs of our patients.”


Supporting organizations:

American Pharmacists Association

American Society of Consultant Pharmacists

American Society of Health-System Pharmacists

College of Psychiatric and Neurologic Pharmacists

National Alliance of State Pharmacy Associations

National Community Pharmacists Association

Media contacts:

APhA: Frank Fortin, [email protected], (202) 223-7189

ASCP: Jim Lewis, [email protected], (724) 288-3995

ASHP: Aretha Hankinson, [email protected], (301) 452-0569

CPNP:  Brenda Schimenti, [email protected], (402) 476-1677

NASPA: Rebecca Snead, [email protected], (804) 285-4431

NCPA: Andie Pivarunas; [email protected], (703) 600-1174




- # -


Posted November 30, 2021

Advance Your Professional Development

View Other Products

Free Board Exam Prep Resources

The Review & Recertification Reward Program (RRRP) includes free access to exam preparation material + enrollment in a recertification plan billed monthly ($10) during your initial recertification cycle. For ASHP members only.

Learn More
Review & Recertification Reward Program (RRRP)

New Edition Available to Order

AHFS Drug Information® 2024 contains the most dependable drug information available—all in one place. It is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses.

Order Today
AHFS 2024 Drug Information